Just as measuring Amyloid Precursor Protein (APP) levels in platelets can serve as a diagnostic tool for assessing Alzheimer’s disease severity [178], it is reasonable to consider protein levels as biomarkers for future complications. The gene discussed is APP; the disease is Alzheimer disease.